Arcinova, a Quotient Sciences company and UK-based contract research development and manufacturing organisation (CRDMO), has announced the appointment of Dr Christian Dowdeswell as new Managing Director.
He takes the reins from co-founder and Managing Director Paul Ryan, who recently announced his retirement.
Christian joins the firm at a busy time for the business, which has recently relaunched with a refreshed brand identity and a renewed focus on delivering integrated drug substance and early drug product services to global biotech and pharmaceutical partners.
More recently, the company has enhanced its aseptic capabilities to ensure full compliance with the latest Annex 1 requirements, further strengthening its ability to support complex and high-quality manufacturing needs.
Commenting on his appointment, Christian said: “Arcinova has an outstanding reputation for innovation, agility and scientific excellence – qualities our clients depend on. Paul has built a strong foundation for success and I’m committed to building on that momentum, driving growth while keeping our customers at the heart of everything we do.”
Bringing over 25 years of sector experience to his role, Christian joins Arcinova from consulting and advisory positions with companies including Nanoform and Pangaea Life Sciences.
